SCHEMBL10083809

SCHEMBL10083809

O=Cc1cc(F)c(F)cc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 8/20 0.47
KEAP1 Q14145 2/20 0.44
NFE2L2 Q16236 1/20 0.44
KDM4E B2RXH2 1/20 0.39
ASPH Q12797 1/20 0.39
KDM8 Q8N371 1/20 0.39
ALB P02768 1/20 0.38
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
ALDH1A1 P00352 3/20 0.35
POLB P06746 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
NSD2 O96028 1/20 0.34
PKM P14618 1/20 0.34
APEX1 P27695 1/20 0.34
CASP3 P42574 1/20 0.34
RECQL P46063 1/20 0.34
CASP6 P55212 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34465712 0.88 ERN1 (0.46) ERN1KEAP1NFE2L2KDM4EALB
SCHEMBL10111663 0.85 ERN1 (0.39) ERN1KDM4EALDH1A1POLBTDP1
SCHEMBL10111667 0.83 ERN1 (0.38) ERN1KDM4EALDH1A1POLBTDP1
SCHEMBL7614681 0.81 ERN1 (0.37) ERN1KDM4EALDH1A1POLBTDP1
SCHEMBL14526673 0.81 ERN1 (0.37) ERN1KDM4EALDH1A1POLBTDP1
SCHEMBL4830274 0.80 KEAP1 (0.54) KEAP1NFE2L2KDM4EASPHKDM8
SCHEMBL20140332 0.78 ERN1 (0.44) ERN1KEAP1NFE2L2KDM4EASPH
SCHEMBL6928663 0.78 KEAP1 (0.52) ERN1KEAP1KDM4EALBALDH1A1
Boric Acid SCHEMBL29160818 0.78 KEAP1 (0.48) KEAP1NFE2L2KDM4EASPHKDM8
Lithium SCHEMBL30497778 0.78 KEAP1 (0.52) KEAP1NFE2L2KDM4EASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132112-A1 COMPOUNDS CTXT PTY LTD (AU) 2026-05-14 US disclosed
EP-4734979-A2 TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-05-06 EP disclosed
EP-4077318-B1 BENZIMIDAZOLE DIMERS AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-10-15 EP disclosed
US-12415785-B2 Compound modulators of sting CTXT PTY LTD (AU) 2025-09-16 US disclosed
CN-114981265-B Compounds of formula (I) CTXT私人有限公司 2025-01-03 CN disclosed
WO-2025006723-A2 TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE CARAWAY THERAPEUTICS, INC. (US) 2025-01-02 WO disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
US-20230062932-A1 COMPOUNDS CTXT PTY LTD. (AU) 2023-03-02 US disclosed
WO-2022266711-A1 SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS Aculeus Therapeutics Pty Ltd (AU) 2022-12-29 WO disclosed
EP-4077318-A1 COMPOUNDS CTXT PTY LTD (AU) 2022-10-26 EP disclosed
CN-114981265-A Compound (I) CTXT私人有限公司 2022-08-30 CN disclosed
WO-2021119753-A1 COMPOUNDS CTXT PTY LIMITED (AU) 2021-06-24 WO disclosed
EP-2632915-B1 BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INT (DE) 2015-08-12 EP disclosed
US-8829200-B2 Benzimidazole inhibitors of leukotriene production BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-09 US disclosed
US-8829200-B2 Benzimidazole inhibitors of leukotriene production BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-09 US disclosed
US-20120277226-A1 BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-11-01 US disclosed
US-20120277226-A1 BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-11-01 US disclosed
WO-2012058254-A1 BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12415785-B2 Compound modulators of sting STING1, IRF3, MAVS ERN1 681/4885KEAP1 331/4885NFE2L2 256/4885
US-20260132112-A1 COMPOUNDS STING1, IRF3, CGAS ERN1 669/4885KEAP1 438/4885NFE2L2 678/4885
US-20120277226-A1 BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION LTB4R, LTB4R2, LTC4S ERN1 2945/4885KEAP1 905/4885NFE2L2 3675/4885
US-20230062932-A1 COMPOUNDS STING1, IRF3, MAVS ERN1 984/4885KEAP1 249/4885NFE2L2 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.